T102C polymorphism in the 5HT2A gene and schizophrenia: Relation to phenotype and drug response variability

Journal of Psychiatry and Neuroscience

Volumn 24, Issue 2, 1999, Pages 141-146

  Joober, Ridha ^a,c   Benkelfat, Chawki ^b   Brisebois, Kateri ^a   Toulouse, André ^a   Turecki, Gustavo ^a   Lal, Samarthji ^c   Bloom, David ^c   Labelle, Alain ^d   Lalonde, Pierre ^e   Fortin, Diane ^a   Alda, Martin ^d   Palmour, Roberta ^b   Rouleau, Guy A ^a  

^a MONTREAL GENERAL HOSPITAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d ROYAL OTTAWA HOSPITAL   (Canada)

^e CENTRE DE RECHERCHE FERNAND SEGUIN   (Canada)

Author keywords

Alleles; Drug resistance; Genetics; Genotype; Pharmacogenetics; Polymorphism (genetics); Receptors, serotonin; Schizophrenia

Indexed keywords

SEROTONIN 2A RECEPTOR; SEROTONIN RECEPTOR;

ADULT; ALLELE; ARTICLE; DRUG EFFECT; FEMALE; GENETIC POLYMORPHISM; GENETICS; HUMAN; MALE; MIDDLE AGED; PHENOTYPE; SCHIZOPHRENIA;

ADULT; ALLELES; FEMALE; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, GENETIC; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, SEROTONIN; SCHIZOPHRENIA;

EID: 0033090841     PISSN: 11804882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Karayiorgou M, Gogos JA. Dissecting the genetic complexity of schizophrenia. Mol Psychiatry 1997;2:211-23.
2. Gershon ES, Martinez M, Goldin L, Gelernter J, Silver J. Detection of marker associations with a dominant disease gene in genetically complex and heterogeneous diseases. Am J Hum Genet 1989;45:578-85.
3. Inayama Y, Yoneda H, Sakai T, Ishida T, Nonomura Y, Kono Y, et al. Positive association between a DNA sequence variant in the serotonin 2A receptor gene and schizophrenia. Am J Med Genet 1996;67:103-5.
4. Williams J, Spurlock G, McGuffin P, Mallet J, Nothen MM, Gill MX, et al. Association between schizophrenia and T102C polymorphism of the 5-hydroxytryptamine type 2a-receptor gene. European Multicentre Association Study of Schizophrenia (EMASS) Group. Lancet 1996;347:1294-6.
5. Spurlock G, Heils A, Holmans P, Williams J, Dsouza UM, Cardno A, et al. A family based association study of t102c polymorphism in 5ht2a and schizophrenia plus identification of new polymorphisms in the promoter. Mol Psychiatry 1998;3:42-9.
6. Malhotra AK, Goldman D, Ozaki N, Breier A, Buchanan R, Pickar D. Lack of association between polymorphisms in the 5-HT2A receptor gene and the antipsychotic response to clozapine. Am J Psychiatry 1996;153:1092-4.
7. Arranz MJ, Lin MW, Powell J, Kerwin R, Collier D. 5HT 2a receptor T102C polymorphism and schizophrenia. Lancet 1996;347:1831-2.
8. 2 receptor gene locus: association with schizophrenia or treatment response not detected. Psychiatr Genet 1996;6:23-27.
9. Williams J, McGuffin P, Nothen M, Owen MJ. Meta-analysis of association between the 5-HT2a receptor T102C polymorphism and schizophrenia. EMASS Collaborative Group. European Multicentre Association Study of Schizophrenia. Lancet 1997;349:1221.
10. Arranz M, Collier D, Sodhi M, Ball D, Roberts G, Price J, et al. Association between clozapine response and allelic variation in 5-HT2A receptor gene. Lancet 1995;346:281-2.
11. 2A receptor gene and response to clozapine. Mol Psychiatry 1998;3:61-6.
12. 2A receptors and clozapine response. Schizophr Res 1998;2:93-9.
13. 2A receptor and response to clozapine. Lancet 1995;346:1108
14. Ichinose H, Nagatsu T. Molecular genetics of hereditary dystonia - mutations in the GTP cyclohydrolase I gene. Brain Res Bull 1997;43:35-8.
15. Blacker D, Tanzi RE. The genetics of Alzheimer disease: current status and future prospects. Arch Neurol 1998; 55:294-6.
16. Breitner JC, Jarvik GP, Plassman BL, Saunders AM, Welsh KA. Risk of Alzheimer disease with the epsilon4 allele for apolipoprotein E in a population-based study of men aged 62-73 years. Alzheimer Dis Assoc Disord 1998;12:40-4.
17. Brenner HD, Dencker SJ, Goldstein MJ, Hubbard JW, Keegan DL, Kruger, G, et al. Defining treatment refractoriness in schizophrenia. Schizophr Bull 1990;16:551-61.
18. Brown WA. Neuroleptic responsive versus resistant patients. In: Shriqui CL, Nasrallah HA, editors. Contemporary issues in the treatment of schizophrenia. Washington (DC): American Psychiatric Press; 1995. p. 479-96.
19. Kolakowska T, Williams AO, Ardern M, Reveley MA, Jambor K, Gelder MG, et al. Schizophrenia with good and poor outcome. I: Early clinical features, response to neuroleptics and signs of organic dysfunction. Br J Psychiatry 1985;146:229-39.
20. Szymanski S, Lieberman JA, Alvir JM, Mayerhoff D, Loebel A, Geisler S, et al. Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients. Am J Psychiatry 1995;152:698-703.
21. Lindstrom EM, Ohlund LS, Lindstrom LH, Ohman A. Symptomatology and electrodermal activity as predictors of neuroleptic response in young male schizophrenic inpatients. Psychiatry Res 1992;42:145-58.
22. McDermott BE, Sautter FJ, Garver DL. Heterogeneity of schizophrenia: relationship to latency of neuroleptic response. Psychiatry Res 1991;37:97-103.
23. Mazure CM, Nelson JC, Jatlow PI, Bowers MB. Plasma free homovanillic acid (HVA) as a predictor of clinical response in acute psychosis. Biol Psychiatry 1991;30:475-82.
24. Bartlett EJ, Brodie JD, Simkowitz P, Schlosser R, Dewey SL, Lindenmeyer JP, et al. Effect of haloperidol challenge on regional brain metabolism in neuroleptic-responsive and nonresponsive schizophrenic patients. Am J Psychiatry 1998;155: 343.
25. Breier A, Schreiber JL, Dyer J, Pickar D. National Institute of Mental Health longitudinal study of chronic schizophrenia. Prognosis and predictors of outcome. Arch Gen Psychiatry 1991; 48:239-46.
26. Miller RS, Peterson GM, McLean S, Westhead TT, Gillies P. Monitoring plasma levels of fluphenazine during chronic therapy with fluphenazine decanoate. J Clin Pharm Ther 1995;20:55-62.
27. Wolkin A, Barouche F, Wolf AP, Rotrosen J, Fowler JS, Shiue CYX, et al. Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia. Am J Psychiatry 1989;146:905-8.
28. Meltzer HY, Lee M, Cola P. The evaluation of treatment resistance: biologic implications. J Clin Psychopharmacol 1998;18:5s-11s.
29. Szymanski S, Lieberman J, Pollack S, Kane JM, Safferman A, Munne RX, et al. Gender differences in neuroleptic nonresponsive clozapine-treated schizophrenics. Biol Psychiatry 1996;39: 249-54.
30. Nurnberger JI Jr, Blehar MC, Kaufmann CA, York-Cooler C, Simpson SGX, Harkavy-Friedman J, et al. Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative. Arch Gen Psychiatry 1994;51:849-59, 863-4.
31. Woerner MG, Mannuzza S, Kane JM. Anchoring the BPRS: an aid to improved reliability. Psychopharmacol Bull 1988;24:112-7.
32. Warren JT, Peacock ML, Rodriguez LC, Fink JK. An Msp 1 polymorphism in the human serotonin receptor gene (HTR2): detection by DGGE and FLP analysis. Hum Mol Genet 1993;2:338.
33. Masellis M, Basile V, Meltzer HY, Lieberman JA, Sevy S, Macciardi FM, et al. Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. Neuropsychopharmacology 1998;19:123-32.
34. Endicott J, Spitzer RL, Fleiss JL, Cohen J. The global assessment scale, a procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 1976;33:766-71.
35. 2A receptor influences amplitude and timing of intracellular calcium mobilization. J Neurochem 1997;68:2186-93.